Hospital
Second Affiliated Hospital of Harbin Medical University哈尔滨医科大学附属第二医院
At a glance
Published values only, each read from the record this page is built on. The listings behind them are in the section below.
-
Fudan University hospital rankings A+ General list, 2023
-
Published research 19 PubMed records we hold for this hospital (the newest twenty per hospital)
-
Registered studies 4 records we hold for this hospital, as registered
Rankings & accreditation
These listings are published by the bodies that run them, not by this site. Every line carries the year it was published and a link to its source; this is not a paid or promoted listing.
Fudan University hospital rankings
| Item | Rank / tier | Year | Caliber | Source |
|---|---|---|---|---|
| General list | A+ | 2023 | Tier only; hospitals in the same tier are not ordered against each other | https://rank.cn-healthcare.com/fudan/national-general |
Conditions treated here
Conditions this site files under the specialties above. It is a record of the listings, not a recommendation.
For international patients
A line appears here only where we hold a record for it. A line that is missing has not been verified - ask us and we will put the question to the hospital.
Hospital details
- Chinese name
- 哈尔滨医科大学附属第二医院
- English name
- Second Affiliated Hospital of Harbin Medical University
Values written in Chinese are quoted as published by the source.
The grade list reference is the date or review batch the official list was published under; it is quoted in the source's language.
Evidence for this condition
Selected using official public data sources
-
Colorectal cancer
Published research
- A Nomogram Integrating Deep Learning and Immunoscore for Predicting Distant Metastasis and Prognosis in Rectal Cancer. Academic radiology, 2026
- Preclinical evaluation of [(68)Ga]Ga-MRCP: a potential radiotracer for imaging PD-L1 expression in colorectal cancer. Bioorganic chemistry, 2026
6 more published studies
PubMed indexes 8 papers on this condition that name this hospital.
Also ranked: Otorhinolaryngology nominated in the Fudan list.
-
Breast cancer
Published research
- The YAP-TEAD4 inhibitor M511-0965 suppresses triple-negative breast cancer progression by downregulating TGFB2. Translational oncology, 2026
- Benefit-Hematotoxicity Stratification in Patients with Triple-Negative Breast Cancer Receiving Platinum-Based Neoadjuvant Therapy: A Multitask Deep Learning Study. Cancers, 2026
2 more published studies
PubMed indexes 4 papers on this condition that name this hospital.
Also ranked: Otorhinolaryngology nominated in the Fudan list.
-
Lung cancer
Published research
- Integration of habitat radiomics and 2.5D deep features from (18)F-FDG PET/CT for noninvasive prediction of PD-L1 TPS ≥ 50% in non-small cell lung cancer. European journal of radiology, 2026
PubMed indexes 1 paper on this condition that names this hospital.
Also ranked: Otorhinolaryngology nominated in the Fudan list.
-
Liver cancer
Published research
- Retraction notice to “RNA-seq shows angiopoietin-like 4 promotes hepatocellular carcinoma progression by inducing M2 polarization of tumor-associated macrophages” [Int. J. Biol. Macromol. 287 (2025) 138523]. International journal of biological macromolecules, 2026
- PTPN14 functions as an oncogenic promoter in colon adenocarcinoma and liver hepatocellular carcinoma via Notch Signaling. Cellular signalling, 2026
PubMed indexes 2 papers on this condition that name this hospital.
Also ranked: Otorhinolaryngology nominated in the Fudan list.
-
Stomach cancer
Published research
- CMTM3 links inflammation-related transcriptional dysregulation to immune and therapeutic stratification in gastric cancer. Translational oncology, 2026
PubMed indexes 1 paper on this condition that names this hospital.
Also ranked: Otorhinolaryngology nominated in the Fudan list.
-
Prostate cancer
Published research
- Transcription Factor 21 Inhibits Prostate Cancer Progression via Transcriptional Repression of PSAT1. The Tohoku journal of experimental medicine, 2026
- AI-Assisted Prostate Cancer Diagnosis Using Biparametric MRI and PI-RADS v2.1: Performance Comparison Between Novice-Level and Experienced Readers. Journal of magnetic resonance imaging : JMRI, 2026
PubMed indexes 2 papers on this condition that name this hospital.
Also ranked: Otorhinolaryngology nominated in the Fudan list.
-
Thyroid cancer
Published research
- The role of plectin as a druggable target in papillary thyroid carcinoma: therapeutic potential of troglitazone. Frontiers in immunology, 2026
PubMed indexes 1 paper on this condition that names this hospital.
Also ranked: Otorhinolaryngology nominated in the Fudan list.
-
Nasopharyngeal carcinoma
Fudan specialty reputation ranking 2023
- Otorhinolaryngology nominated https://www.fdygs.com/news2023-1.aspx
Other hospitals in Harbin
Source & evidence
- Source URL
- https://rank.cn-healthcare.com/fudan/national-general
- Source scheme
- https
- Source type
- Third-party compilation
- Evidence level
- B - hospital self-statement or authoritative media
- Retrieved on
- 2026-09-24